Order and manage both germline and tumor genomic tests right inside the EMR platform you already use. Fewer steps, faster turnaround, concordant results, and no more juggling multiple labs or tracking down fragmented reports.
With our comprehensive oncology-focused portfolio, expanding your Myriad Oncology ordering in OncoEMR isn’t just easier—it’s better for you and your patients.
All-in-one ordering
Seamlessly order MyRisk® Hereditary Cancer Test, Precise Tumor® Molecular Profile Test, MyChoice® CDx HRD Myriad HRD Companion Diagnostic Test, and immunohistochemistry (IHC) testing for PD-L1 and Folate receptor alpha (FOLR1/FRα) in a single workflow.
Concordant results
With Myriad Oncology, you get concordant results across the entire patient journey, avoiding inconsistencies that arise when multiple labs interpret variants differently.
One-page summary
You’ll receive clear, clinically actionable insights delivered directly to your EMR, along with a treatment-focused summary sheet consolidating germline and tumor genomic information on a single page that is easy to read and easy to share with patients.
Faster turnaround
Speed up turnaround times and increase visibility across your care team. No more switching between portals and paper TRFs. No more juggling multiple labs or tracking down fragmented reports.
Guideline adherence
With ASCO recommending germline testing for all eligible patients regardless of tumor results, Myriad simplifies adherence to these guidelines, helping to ensure that no critical variant or therapy opportunity is missed.1
Myriad can support most EMR platforms you currently use. We offer native integration with most EMR platforms and can build customizable solutions for others.
Coming soon
With Myriad Oncology, results are clear, treatment-focused, and clinically-actionable—making it easier to personalize therapy decisions, identify clinical trials, and support patients with confidence, across the entire patient journey.
By choosing Myriad Oncology, you also get access to our unrivaled suite of services—from pre- and post-test education to billing and clinical support—at no added cost to your clinic or patients.
The MyRisk test provides more answers for more patients by identifying up to 63% of variants other labs cannot definitively classify and offers the industry’s lowest reported rates of BRCA1/2 variants of uncertain significance (VUS) of 1.0%.2,3
The Precise Tumor test utilizes combined DNA and RNA sequencing to detect more fusion and splice variants compared to DNA-only tests, increasing patient eligibility for targeted therapies and clinical trials.4-7
The MyChoice CDx test helps you expand access to PARP inhibitors by identifying 34% more HRD-positive ovarian cancer patients than other tests that only use %LOH.8
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
References: